Fulcrum Therapeutics Announces Results from Phase 1b Pioneer Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics reported positive 12-week data from the 12mg dose cohort of its Phase 1b PIONEER trial of pociredir...
Jon Napitupulu
Brincidofovir: Potential Antiviral for Mpox Treatment
Emergent BioSolutions announced the publication of a review article on the use of its investigational antiviral drug, brincidofovir, for...
NetraMark & Algotx Join Forces to Optimize Atx01 Clinical Trials
NetraMark Holdings Inc., an AI company specializing in clinical trials, and AlgoTherapeutix SAS (AlgoTx), a biotech company developing therapies...
Radiopharm B7-H3 BetaBart RV-01 IND Approved for Phase 1 Study
Radiopharm Theranostics has received FDA Investigational New Drug (IND) application clearance for Betabart (RV-01), a Lu177-B7H3 monoclonal antibody targeting...
FDA Approves BMD as Primary Endpoint for EB613 Osteoporosis Study
Entera Bio received positive feedback from the FDA regarding its New Drug Application (NDA) for EB613, an oral treatment...
Alterity Therapeutics Reports Positive Topline Phase 2 Clinical Trial Data
Alterity Therapeutics announced positive topline data from its open-label Phase 2 clinical trial (ATH434-202) of ATH434 in individuals with...
Reshape Lifesciences® Hosts Inaugural Lap-Band® Surgeon Summit
ReShape Lifesciences is hosting its first Lap-Band Surgeon Summit from August 1st to 3rd, 2025, in Nashville, Tennessee. The...
Rinvoq, Gazyva, and Sotyktu Emerge as Front-Runners for Lupus Care
Biologic use for systemic lupus erythematosus (SLE) is increasing, with nearly 40% of moderate-to-severe SLE patients in the U.S....
Qu Biologics’ Immunomodulator Study in Elderly
Qu Biologics has completed enrollment for its RESILIENCE Study, a Phase 2 clinical trial testing QBKPN SSI, a novel...
Clearmind Medicine starts the leading Israeli Clinical site
Clearmind Medicine Inc. announced the successful initiation of a clinical trial site at Tel Aviv Sourasky Medical Center (TASMC)...